Dartmouth/VA researchers show that adding CRP testing to routine assessments would increase the number of Americans eligible for cholesterol-lowering treatment by about two million if used judiciously, and by over 25 million if used broadly — with most of these people being at low risk for heart attacks or heart disease.
Many doctors should change the way they prescribe pain relievers for chronic pain in patients with or at risk for heart disease based on accumulated evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), with the exception of aspirin, increase risk for heart attack and stroke, according to an American Heart Association statement published in Circulation: Journal of the American Heart Association.
The future of cancer detection and treatment may be in gold nanoparticles ? tiny pieces of gold so small they cannot be seen by the naked eye.
Teens who start having sex significantly earlier than their peers also show higher rates of delinquency in later years, new research shows.
Pelvic and prostate exams provoke jitters for medical students. Carla Pugh, an assistant professor of surgery at Northwestern University, invented and patented a sensor technology in exam simulators to show students whether they have the right touch in these sensitive exams without a patient ever having to yell “Ouch!” Pugh has also invented teaching technologies for other difficult medical procedures. She was honored for being a trailblazer in a national museum.
The U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta(R) (duloxetine HCl) for the treatment of generalised anxiety disorder (GAD), Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim announced today.
Chronic kidney disease (CKD), a serious and progressive medical condition, has been and remains under-identified. While it is easy and inexpensive to test for kidney function, people who are at high risk for CKD are not routinely screened.
Industry-funded studies of breast cancer therapies are more likely to report positive results than non-pharmaceutical funded studies, researchers from the University of North Carolina at Chapel Hill and the Dana Farber Cancer Institute have found.
Breast cancer treatment trials supported by the pharmaceutical industry are more likely to report positive results than non-sponsored studies, according to a study to be published in the April 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
African and African American women are more likely to die of breast cancer than their white counterparts because they tend to get the disease before the menopause, suggests new research from the University of East Anglia and the Children’s Hospital Boston in collaboration with researchers in the US and Italy.